Clinical Trials
22 trialsA Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
A Phase II Study of SKB571 in Patients With Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Minghui Pharmaceutical (Hangzhou) Ltd
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
A Phase â…¡ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
RemeGen Co., Ltd.
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Tongji Hospital
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
KEYNOTE F19
Evopoint Biosciences Inc.
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Shanghai Pulmonary Hospital, Shanghai, China